Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions

Radiologic Detection and Characterization of Benign and Malignant Liver Lesions in Contrast-Enhanced MRI

This clinical trial studies contrast-enhanced magnetic resonance imaging (MRI) in detecting nonmalignant and malignant liver lesions. Diagnostic procedures, such as MRI, may help find and diagnose nonmalignant and malignant liver lesions. Contrast agents, such as gadoxetate disodium and gadobutrol, may help doctors to see MRI images more clearly.

PRIMARY OBJECTIVES:

I. To compare the specificity of contrast enhanced MRI using a liver specific agent Eovist (gadoxetate disodium) versus the combined use of Eovist and an intravascular-extracellular agent Gadavist (gadobutrol) for the radiologic detection and characterization of liver lesions via clinical stability and follow up imaging.

OUTLINE:

Patients receive gadoxetate disodium intravenously (IV) over 1 minute and undergo MRI. Patients then receive gadobutrol IV over 1 minute at the 20 minute mark during MRI.

Inclusion Criteria:

• Patients with the most recent abdominal magnetic resonance (MR) study obtained within 3 months +/- 1 week
• Patients with renal function (estimated glomerular filtration rate [eGFR] >= 30)
• Any disease type

Exclusion Criteria:

• Pregnant women
• Patients with impaired renal function (eGFR < 30)
• Patients with surgical implants and/or metallic foreign bodies non-compatible with the MR magnet
• Patients with contraindications to the use of intravenous contrast such as allergic type reactions